This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials

Taking stock of the drug industry, from the lab to the medicine chest

March 26, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | This Canadian company's AI tool could help drugmakers cut risk in late-stage cancer trials Canadian company Altis Labs uses AI tool to review lung cancer CT scans to predict future patient survival, helping drugmakers improve trial design. By Brittany Trang STAT+ | Wave to submit Duchenne drug for approval after Phase 2 success The results set the stage for a new therapeutic option for patients with the rare disease, which primarily affects young boys. By Allison DeAngelis and Jason Mast Altis says its AI tool can cut risk in cancer trials Today's biotech news covers an AI tool for cancer trials, proposals to make ivermectin over-the-counter, and study replication. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser